Pasquale Niscola
April 27, 2024
Cancers (Basel). 2024 Apr 19;16(8):1563. doi: 10.3390/cancers16081563.
ABSTRACT
Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.
PMID:38672645 | DOI:10.3390/cancers16081563
Добавить комментарий